FDA Approves Novartis Kymriah CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular Lymphoma

Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1.

“We are on a mission to build on our pioneering work in cell therapy and continue to innovate for patient impact.

”
Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, is the foundation of the Novartis commitment to CAR-T cell therapy.

We continue to pioneer in cell therapy, leveraging our vast experience to develop next-generation CAR-T cell therapies.

The patient’s health care provider will do blood tests to check all their blood cell counts after treatment with KYMRIAH.